A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Status: | Active, not recruiting |
---|---|
Conditions: | Breast Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/21/2019 |
Start Date: | May 23, 2016 |
End Date: | February 26, 2021 |
monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to evaluate the effectiveness of abemaciclib plus trastuzumab
with or without fulvestrant or chemotherapy in women with hormone receptor positive (HR+),
human epidermal growth factor receptor 2 positive (HER2+) locally advanced or metastatic
breast cancer after prior exposure to at least two HER2-directed therapies for advanced
disease.
with or without fulvestrant or chemotherapy in women with hormone receptor positive (HR+),
human epidermal growth factor receptor 2 positive (HER2+) locally advanced or metastatic
breast cancer after prior exposure to at least two HER2-directed therapies for advanced
disease.
Inclusion Criteria:
- diagnosis of HR+, HER2+ breast cancer (BC)
- unresectable locally advanced recurrent BC or metastatic BC
- adequate tumor tissue available prior to randomization
- measurable and/or non-measurable disease according to Response Evaluation Criteria in
Solid Tumors (RECIST) version 1.1
- previously received:
- at least 2 HER2-directed therapies for advanced disease
- participant must have received trastuzumab emtansine (T-DM1) in any disease
setting
- must have received a taxane in any disease setting
- may have received any endocrine therapy (excluding fulvestrant)
- have postmenopausal status
- performance status (PS) of 0 to 1 on the Eastern Cooperative Oncology Group scale
- left ventricular ejection fraction (LVEF) of 50% or higher at baseline
- adequate organ function
- negative serum pregnancy test at baseline (within 14 days prior to randomization) and
agree to use medically approved precautions to prevent pregnancy during the study and
for 12 weeks following the last dose of abemaciclib id menopause induced by
gonadotropin-releasing hormone (GnRH) agonist or radiation
- discontinued previous localized radiotherapy for palliative purposes or for lytic
lesions at risk of fracture at least 2 weeks prior to randomization and recovered from
the acute effects of therapy
- discontinued all previous therapies for cancer (including chemotherapy, radiotherapy,
immunotherapy, and endocrine therapy), except trastuzumab, for at least 21 days for
myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving
study drug, and recovered from the acute effects of therapy
- are able to swallow capsules
Exclusion Criteria:
- have visceral crisis
- known central nervous system (CNS) metastases that are untreated, symptomatic, or
require steroids to control symptoms
- had major surgery within 14 days prior to randomization
- received prior treatment with any cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor
- received treatment with a drug that has not received regulatory approval for any
indication within 14 or 21 days of randomization for a nonmyelosuppressive or
myelosuppressive agent, respectively
- have serious preexisting medical conditions that, in the judgment of the investigator,
would preclude participation in this study
- history within the last 6 months of symptomatic congestive heart failure, myocardial
infarction, or unstable angina
- history within the last 12 months of any of the following conditions: syncope of
cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden
cardiac arrest
- history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of
the cervix), unless in complete remission with no therapy for a minimum of 3 years
- active bacterial, fungal infection, or detectable viral infection
- have received any recent (within 28 days prior to randomization) live virus
vaccination
- hypersensitivity to trastuzumab, murine proteins, fulvestrant, or to any of the
excipients
We found this trial at
32
sites
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Maura Dickler
Phone: 646-888-4560
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
1045 North 30th Street
Billings, Montana 59101
Billings, Montana 59101
406-255-8470
Principal Investigator: Michael Kidd
Phone: 406-238-7330
Click here to add this to my saved trials
3840 Broadway
Fort Myers, Florida 33901
Fort Myers, Florida 33901
(239) 275-6400
Principal Investigator: Lowell Hart
Phone: 239-274-9930
Click here to add this to my saved trials
11143 Parkview Plaza Dr # 100
Fort Wayne, Indiana 46845
Fort Wayne, Indiana 46845
(260) 484-8830
Principal Investigator: Sunil Babu
Phone: 317-436-0800
Fort Wayne Medical Oncology and Hematology Fort Wayne Medical Oncology and Hematology provides state-of-the-art cancer...
Click here to add this to my saved trials
1400 South Orange Avenue
Orlando, Florida 32806
Orlando, Florida 32806
(407) 648-3800
Principal Investigator: Regan Rostorfer
Phone: 321-841-1946
M.D. Anderson Cancer Center at Orlando For more than twenty years, our cancer center has...
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Lupe Salazar
Phone: 206-616-8503
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Jane Meisel
Phone: 404-778-1900
Click here to add this to my saved trials
Atlanta, Georgia 30341
Principal Investigator: Amelia Zelnak
Phone: 770-205-5292
Click here to add this to my saved trials
Bakersfield, California 93309
Principal Investigator: David Kanamori
Phone: 661-616-1619
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Sara Tolaney
Phone: 617-632-3800
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Brooklyn, New York 11212
Principal Investigator: Vladimir Gotlieb
Phone: 718-240-6208
Click here to add this to my saved trials
Click here to add this to my saved trials
East Setauket, New York 11733
Principal Investigator: Noshir DaCosta
Phone: 631-751-3000
Click here to add this to my saved trials
Englewood, Colorado 80112
Principal Investigator: SMO Catholic Health Oncology Netwo
Phone: 720-784-1304
Click here to add this to my saved trials
Fort Worth, Texas 76104
Principal Investigator: Robyn Young
Phone: 817-759-7023
Click here to add this to my saved trials
Fullerton, California 92835
Principal Investigator: William Lawler
Phone: 714-446-5804
Click here to add this to my saved trials
Lake Success, New York 11042
Principal Investigator: Francis Arena
Phone: 516-466-6611
Click here to add this to my saved trials
Click here to add this to my saved trials
Lexington, Kentucky 40509
Principal Investigator: Jessica Moss
Phone: 859-629-7123
Click here to add this to my saved trials
Los Angeles, California 90024
Phone: 310-824-1934
Click here to add this to my saved trials
1441 Eastlake Avenue
Los Angeles, California 90033
Los Angeles, California 90033
Principal Investigator: Janice Lu
Phone: 323-865-3962
Click here to add this to my saved trials
757 Westwood Plaza
Los Angeles, California 90024
Los Angeles, California 90024
(310) 825-9111
Principal Investigator: Sara Hurvitz
Phone: 310-829-5471
UCLA Medical Center Founded in 1955, UCLA Medical Center became Ronald Reagan UCLA Medical Center...
Click here to add this to my saved trials
230 25th Ave N
Nashville, Tennessee 37203
Nashville, Tennessee 37203
(615) 329-7274
Principal Investigator: SMO Sarah Cannon Research Inst.
Phone: 615-239-7615
Sarah Cannon Cancer Center People who live with cancer
Click here to add this to my saved trials
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
Nashville, Tennessee 37023
615-320-5090
Principal Investigator: Denise Yardley
Phone: 615-340-2827
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Jennifer Matro
Phone: 215-662-7096
Click here to add this to my saved trials
Plantation, Florida 33324
Principal Investigator: Carmen Calfa
Phone: 954-210-1168
Click here to add this to my saved trials
Puyallup, Washington 98372
Principal Investigator: Sibel Blau
Phone: 253-428-8700
Click here to add this to my saved trials
Redondo Beach, California 90277
Principal Investigator: David Chan
Phone: 310-750-3376
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Ciara O'Sullivan
Phone: 507-284-8665
Click here to add this to my saved trials
Saint Petersburg, Florida 33705
Principal Investigator: Gail Shaw Wright
Phone: 727-216-1143
Click here to add this to my saved trials
Santa Monica, California 93454
Principal Investigator: Robert Dichmann
Phone: 805-346-3461
Click here to add this to my saved trials
5300 Tallman Ave NW
Seattle, Washington 98122
Seattle, Washington 98122
(206) 782-2700
Principal Investigator: Erin Ellis
Phone: 206-215-3086
Swedish Medical Center Since 1910, Swedish has been the region's hallmark for excellence in health...
Click here to add this to my saved trials